Pharminent · Daily Brief
October 23, 2026
Regulatory & Approvals
FDA accepts Biohaven’s new submission for Vyglxia
US regulators have accepted a new submission for Biohaven’s rare disease drug Vyglxia (troriluzole), which had previously been rejected.
BioPharma Dive →
FDA grants Ultomiris accelerated approval in the US
The FDA has granted accelerated approval to Ultomiris in the United States.
PharmExec →
FDA launches neuroscience product development program NAIN
The FDA announced the launch of the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency program aligned with the Trump Administration’s efforts to accelerate medical innovation and deliver breakthrough treatments.
FDA →
NICE backs five AI prostate cancer tools for NHS use
NICE has backed temporary NHS use of five AI tools that help detect prostate cancer on MRI scans while further evidence on their value is gathered.
Pharmaphorum →
AMA and EMA publish joint Ebola vaccine development guidance
The EMA’s Emergency Task Force and the African Medicines Agency published a joint position paper to support the timely start of clinical trials for potential Ebola vaccines.
EMA →
Clinical Data
Moderna and Merck’s melanoma vaccine cuts recurrence risk 42%
Moderna and Merck released full results showing their personalized mRNA cancer vaccine intismeran combined with Keytruda reduced the risk of relapse or death by 42% compared with standard treatment in a melanoma trial, with the data put out ahead of an ESMO presentation following a data breach. Shares of both companies fell on the results, which one analyst described as triggering a “sell-the-news reaction.”
BioPharma Dive →$MRK$MRNA
Tango reports 82% response rate in advanced pancreatic cancer
Tango Therapeutics reported that an experimental drug combination produced tumor responses in 82% of patients with a certain type of advanced pancreatic cancer.
STAT →
Alnylam’s Huntington’s gene-silencing drug shows early-study promise
Alnylam said its gene-silencing drug for Huntington’s disease showed promise in an early-stage study, though it remains to be seen whether the drug slows disease progression.
STAT →$ALNY
Deals & Partnerships
Alcon to acquire Neurotech Pharmaceuticals for $550 million
Alcon is acquiring Neurotech Pharmaceuticals for $550 million, gaining the rare vision disorder cell therapy Encelto and the platform technology behind it.
MedCity News →
Celltrion licenses Kaigene’s antibody KG013 in $580M deal
Celltrion has acquired exclusive global development and commercialization rights to Kaigene’s investigational monoclonal antibody KG013 in a deal worth up to $580 million.
Pharmaceutical Technology →
Boehringer Ingelheim and Microsoft partner on AI in clinical research
Boehringer Ingelheim and Microsoft entered a strategic collaboration to examine the use of AI in clinical research, starting with studies in lung health.
Pharmaceutical Technology →
Business & Finance
US Treasury proposes curbs on Chinese biotech deals
The US Treasury has issued a proposal that could restrict future deals for Chinese-originated drug candidates, which have become a major source of assets for pharma groups.
Pharmaphorum →
Lycia Therapeutics prices upsized $318M IPO
Protein degrader developer Lycia Therapeutics priced an upsized initial public offering raising $318 million, with proceeds supporting three protein-degrading medicines in development for allergic conditions and the autoimmune disorder Graves’ disease.
BioPharma Dive →
Forwarded this? Get your copy free
Sign up free →
Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.